Fig. 4: Sensitivity of palbociclib-resistant cells to the combination of capivasertib and fulvestrant. | npj Breast Cancer

Fig. 4: Sensitivity of palbociclib-resistant cells to the combination of capivasertib and fulvestrant.

From: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models

Fig. 4

A T47D and B MCF7 parental and PalboR cells plated without palbociclib overnight, then treated with capivasertib and fulvestrant at concentrations indicated for 5 days. Cell count normalised to DMSO control (100%) and cell count at the time of dosing (0%). Mean of A 4 and B 3 independent experiments. C T47D and D MCF7 parental and PalboR cells treated with capivasertib and fulvestrant at concentrations indicated for 5 days. Normalised cell counts analysed by Genedata Screener Compound Synergy Extension. Representative combination clusters are shown (0 represents DMSO control, values 1–100 represent cell growth inhibition, values > 100 represent cell death) with Highest Single Agent (HSA) excess heatmaps (highlights dose range where combination benefit was detected) from representative experiment. Tables summarise the range of HSA scores for 3+ independent experiments. E Parental and PalboR T47D and MCF7 cell confluence measured by Incucyte S3. Cells treated 4 days on 3 days off 500 nM capivasertib, continuous 1 nM fulvestrant, or combination for ≥14 days as indicated. F Relative growth inhibition following monotherapy and combination treatment. Confluence calculated at day 18 or 80% control confluence (time point represented by dotted vertical lines on (E). Representative data of ≥3 independent experiments shown with ordinary 1-way ANOVA (Analysis of Variance) statistical analysis *p < 0.05; **p < 0.01; ***p < 0.005, ****p < 0.001.

Back to article page